| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-06-01 |
| タイトル |
|
|
タイトル |
Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
IVIM-MRI |
| キーワード |
|
|
主題 |
immune therapy |
| キーワード |
|
|
主題 |
anti-programmed death-1 therapy |
| キーワード |
|
|
主題 |
anti-PD-1 therapy |
| キーワード |
|
|
主題 |
pseudoprogression |
| キーワード |
|
|
主題 |
atypical radiologic response |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Karayama, Masato
Yoshizawa, Nobuko
Sugiyama, Masataka
Mori, Kazutaka
Yasui, Hideki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakamura, Yutaro
Inui, Naoki
Goshima, Satoshi
Suda, Takafumi
Takehara, Yasuo
|
| 書誌情報 |
Lung Cancer
巻 143,
p. 47-54,
発行日 2020-05
|
| 出版者 |
|
|
出版者 |
Elsevier |
| 権利 |
|
|
権利情報 |
Copyright 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objectives: Conventional evaluation of anti-tumor activity on the basis of tumor size is inadequate for immune checkpoint inhibitors (ICIs). We therefore aimed to assess the usefulness of intravoxel incoherent motion magnetic resonance imaging (IVIM-MRI) for evaluation of the therapeutic efficacy of ICIs.
Materials and Methods: A chest IVIM-MRI was performed before and 2, 4, and 8 weeks after administration of ICIs in patients with advanced non-small-cell lung cancer. Apparent diffusion coefficient (ADC), skewness of ADC (ADCskew), kurtosis of ADC (ADCkurt), true diffusion coefficient (D), pseudodiffusion coefficient (D*), and perfusion fraction (f) were evaluated at each evaluation point and changes from the baseline (Δ).
Results: Twenty patients were enrolled in this study. An increased ADC 8 weeks and decreased ADCkurt and ΔADCkurt 4 weeks after ICIs was associated with objective responses and longer progression-free survival (PFS). A decreased ΔADCskew at 4 weeks was associated with objective responses, disease control, and longer PFS and overall survival. There was no correlation between the efficacy of ICIs and D, D* and f. All of three patients who had pseudoprogression had decreased ΔADCskew at 4 weeks and two of them had decreased ΔADCkurt at 4 weeks. Inversely, all five patients who had progressive disease (PD) did not have increased ΔADCskew at 4 weeks and only one of them had decreased ΔADCkurt at 4 weeks.
Conclusions: Changes in histograms of ADC may be useful for predicting long-term efficacy and distinguishing between pseudoprogression and actual PD after ICIs. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0169-5002 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1872-8332 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32203770 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.lungcan.2020.03.013 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Lung Cancer-143-47.pdf (2.2 MB)
.png)
